Frequency Therapeutics

300 Technology Square, 8th Floor
Cambridge
Massachusetts
02139
United States

Email: frequencytx@macbiocom.com

Show jobs for this employer

About Frequency Therapeutics

Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. Our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the U.S. alone. Our platform technology is founded on discoveries in progenitor cell biology by Bob Langer, Sc.D. at MIT and Jeff Karp, Ph.D., at Harvard, with contributions from Xiaolei Yin, Ph.D. and other members of the Karp Lab at Harvard and Brigham & Women's Hospital.
YEAR FOUNDED:
2015
LEADERSHIP:
Co-founder and CEO: David Luccino
Co-founder and CSO: Chris Loose, Ph.D.
Co-founder and Vice President, Biology and Regenerative Medicine: Will Mclean, Ph.D.
COO: Michael Jirousek, Ph.D.
CMO: Peter C. Weber, M.D., M.B.A.
Senior Vice President, Drug Development and Technical Operations: Raj Manchanda, Ph.D.
TECHNOLOGY:
Please click here for Frequency Therapeutics' technology.

32 articles with Frequency Therapeutics